Law360, New York (September 14, 2006, 12:00 AM ET) -- The U.S. pharmaceutical unit of Belgian chemicals firm Solvay SA has settled a pair of patent-infringement lawsuits with two generic drug makers over a treatment for low testosterone, or “Low T.”
The settlement puts to rest lawsuits filed in August 2003 against generic drug makers Watson Pharmaceuticals Inc. and a partner of Par Pharmaceutical Companies Inc. in the U.S. District Court for the Northern District of Georgia.
The lawsuits were filed by Marietta, Georgia-based Unimed Pharmaceuticals Inc.—a subsidiary of Solvay Pharmaceuticals Inc.—after both defendants filed Abbreviated...
Concessions Mark Solvay Settlement
To view the full article, take a free trial now.
